title: Vascular aphasia outcome after intravenous recombinant tissue plasminogen activator thrombolysis for ischemic stroke.
abstract: BACKGROUND
  No data about the specific outcome of aphasia after thrombolysis are available. Our aim was to describe the severity and type of aphasia after stroke thrombolysis.
  
  
  METHODS
  This retrospective cohort study included consecutive aphasic patients hospitalized in the Stroke Unit of Dijon (University Hospital, France) between 2004 and 2009 for a first-ever ischemic stroke of the left middle cerebral artery. Aphasic syndromes and their severity (French version of the Boston Diagnostic Aphasia Examination) were evaluated during the first week and 3 months after stroke.
  
  
  RESULTS
  In multivariate analyses, the severity of aphasia in the 37 thrombolysed patients was milder than in the 38 nonthrombolysed patients during the first week (adjusted OR = 10.13, 95% CI: 2.43-42.28, p = 0.002) and at 3 months (adjusted OR = 8.44, 95% CI: 2.76-25.80, p = 0.001). The frequency of mild aphasia (conduction or atypical) was not significantly higher in thrombolysed patients during the first week after stroke (adjusted OR = 5.80, 95% CI: 0.82-41.16, p = 0.079).
  
  
  CONCLUSIONS
  The severity of aphasia during the first week and 3 months after stroke is milder in thrombolysed than in nonthrombolysed patients, perhaps because of a greater frequency of conduction and mild atypical aphasia.
authors.affiliation: Department of Neurology, Memory Centre, University Hospital, Dijon, France.
authors.forename: A
authors.initials: A
authors.lastname: Jacquin
authors.forename: M-E
authors.initials: ME
authors.lastname: Virat-Brassaud
authors.forename: O
authors.initials: O
authors.lastname: Rouaud
authors.forename: G-V
authors.initials: GV
authors.lastname: Osseby
authors.forename: C
authors.initials: C
authors.lastname: Aboa-Eboulé
authors.forename: M
authors.initials: M
authors.lastname: Hervieu
authors.forename: M
authors.initials: M
authors.lastname: Ménassa
authors.forename: F
authors.initials: F
authors.lastname: Ricolfi
authors.forename: M
authors.initials: M
authors.lastname: Giroud
authors.forename: Y
authors.initials: Y
authors.lastname: Béjot
mesh_terms: D000368:Aged; D001037:Aphasia / Q000175:diagnosis / Q000209:etiology*; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000150:complications* / Q000188:drug therapy*; D007807:Language Tests; D008297:Male; D015999:Multivariate Analysis; D012189:Retrospective Studies; D012720:Severity of Illness Index; D020521:Stroke / Q000150:complications / Q000188:drug therapy; D015912:Thrombolytic Therapy / Q000009:adverse effects; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator